PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

ARCH Venture Partners

Chicago, ILARCH-VENTURE-PARTNERS-BIO
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

Deep science venture firm with emphasis on life sciences, backing breakthrough therapeutics companies.

Classification
Slugarch-venture-partners-bio
HQChicago, IL
Stage FocusPrimarily seed and Series A in deep tech and life science…
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

ARCH is the real deal for deep tech founders who actually have breakthrough science, not just another SaaS tool with AI sprinkled on top. They've been doing this since before 'deep tech' was a buzzword and have the scientific chops to understand what you're building. The flip side? They move slowly, do serious diligence, and won't invest unless they truly believe you're creating something fundamentally new. If you're looking for quick cash to scale a proven model, look elsewhere. But if you've got legitimate IP and need investors who won't panic when your clinical trial takes three years, ARCH is gold.

KEY TAKEAWAYS
  • Best for: University spinouts and breakthrough science companies with long development cycles
  • Watch out for: Slow decision-making and intense technical diligence process
  • Known for: Deep scientific credibility and patience with complex R&D timelines
Investment Thesis

ARCH invests in breakthrough science and technology companies, particularly in life sciences, physical sciences, and computing. They focus on university spinouts and deep tech companies that can create new industries through fundamental scientific advances.

Stage & Sector Focus

Primarily seed and Series A in deep tech and life sciences, with heavy emphasis on biotech, materials science, and enterprise software. They'll go earlier than most VCs on university spinouts and are comfortable with long development cycles.

Notable Portfolio
IlluminaExact SciencesJuno TherapeuticsTwisted BioscienceDesktop MetalSyros PharmaceuticalsFate TherapeuticsSeer
Key Partners
Robert Nelsen
Co-Founder and Managing Director

ARCH co-founder and biotech veteran who's been doing this for 30+ years. Known for spotting breakthrough life sciences companies early and having deep scientific credibility. Founders say he's genuinely helpful on complex regulatory and partnership issues.

Keith Crandell
Managing Director

Joined from Amgen where he led corporate development. Focuses on therapeutics and has operational experience that founders find valuable. Known for being hands-on without being overbearing.

Kristina Burow
Managing Director

Former McKinsey consultant who moved into venture. Covers both life sciences and physical sciences deals. Founders appreciate her analytical approach and ability to help with strategic planning.

Have a specific question about ARCH Venture Partners?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1